Form 4: Zenas BioPharma Director Boosts Stake

Zenas BioPharma director Patrick G. Enright and affiliated entities acquired common stock totaling 117,255 shares through a private offering on October 9, 2025.

Summary

• Patrick G. Enright, a director of Zenas BioPharma, Inc. (ZBIO), participated in a securities offering.
• The offering closed on October 9, 2025, following a Securities Purchase Agreement entered into on October 7, 2025.
• Enright directly purchased 11,990 shares of common stock at a price of $20.85 per share.
• Longitude Venture Partners IV, L.P. (LVPIV), an entity where Enright is a managing member of the general partner, purchased 105,265 shares of common stock at a price of $19.00 per share.
• Following these transactions, Enright directly holds 11,990 shares.
• LVPIV holds 1,832,669 shares indirectly, and Longitude Prime Fund, L.P. (LPF) holds 774,530 shares indirectly, with Enright disclaiming beneficial ownership except to the extent of his pecuniary interests.

Sentiment

Score: 7

Explanation: The director and affiliated funds increasing their stake in the company through an offering suggests confidence in the company's prospects, which is generally a positive signal for investors.

Positives

• A director and affiliated investment funds increased their stake in Zenas BioPharma, indicating confidence in the company's future prospects.
• The company successfully completed a securities offering, securing capital from investors including its director and related entities.

Risks

• The reporting person disclaims beneficial ownership of shares held by affiliated funds (LVPIV and LPF) except to the extent of their pecuniary interests, which is a standard legal disclosure for indirect holdings and clarifies the extent of direct control.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Patrick G. Enright, a director of Zenas BioPharma, Inc., purchased shares directly.
• Longitude Venture Partners IV, L.P. (LVPIV) and Longitude Prime Fund, L.P. (LPF) are entities where Patrick G. Enright is a managing member of their respective general partners, making their transactions and holdings related party dealings.

Stakeholder Impact

• Shareholders: May view the insider buying as a positive signal of confidence from management and affiliated investment funds.
• Company: Successfully raised capital through the offering, strengthening its financial position.

Key Dates

Recommendation

The director's and affiliated funds' participation in the offering and acquisition of additional shares signals a vote of confidence in Zenas BioPharma's future. While this insider buying is a positive indicator, a Form 4 filing provides limited comprehensive financial context. A thorough investment decision would require reviewing broader financial statements, strategic outlook, and market conditions. Therefore, maintaining a 'hold' position is prudent until further detailed financial analysis can be conducted.

Keywords

Zenas BioPharma, ZBIO, Form 4, insider trading, director purchase, equity offering, common stock, Longitude Capital